The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia.
作者信息
Kim Sung-Hyun
机构信息
Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
出版信息
Korean J Intern Med. 2017 Jan;32(1):67-68. doi: 10.3904/kjim.2016.419. Epub 2017 Jan 1.
Abstract
摘要
相似文献
1
The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia.早期分子预测指标在适合移植的慢性髓性白血病中的作用
Korean J Intern Med. 2017 Jan;32(1):67-68. doi: 10.3904/kjim.2016.419. Epub 2017 Jan 1.
2
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.慢性粒细胞白血病异基因骨髓移植后与移植物抗宿主病相关的微小残留病的不同模式。
J Clin Oncol. 1995 Jul;13(7):1704-13. doi: 10.1200/JCO.1995.13.7.1704.
3
transcripts (MR) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.移植后3个月的转录本（MR）作为慢性髓性白血病长期预后的早期预测指标。
Korean J Intern Med. 2017 Jan;32(1):125-136. doi: 10.3904/kjim.2015.187. Epub 2016 Jun 22.
4
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.异基因移植：骨髓纤维化、慢性粒单核细胞白血病及费城染色体阴性/BCR-ABL阴性慢性粒细胞白血病的一种治疗选择。
Bone Marrow Transplant. 2004 May;33(10):1005-9. doi: 10.1038/sj.bmt.1704472.
5
Significance of detection of BCR/ABL transcript after allogeneic and autologous transplant.异基因和自体移植后检测BCR/ABL转录本的意义。
Bone Marrow Transplant. 1994;14 Suppl 3:S62-7.
6
Essential thrombocythemia after allogeneic bone marrow transplantation for chronic myelogenous leukemia.慢性粒细胞白血病异基因骨髓移植后发生的原发性血小板增多症。
Bone Marrow Transplant. 1998 Jul;22(1):107-9. doi: 10.1038/sj.bmt.1701292.
7
8
Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
Bone Marrow Transplant. 1990 May;5(5):353-6.
9
Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.异基因骨髓移植后慢性髓性白血病患者治疗决策的分子基础。
Haematologica. 2000 Oct;85(10):1072-82.
10
Lymphoid blast crisis of chronic myelogenous leukemia occurring more than 11 years after receiving an allogeneic bone marrow transplant for chronic myelogenous leukemia in myeloid blast crisis at onset.
Bone Marrow Transplant. 2003 Feb;31(3):211-3. doi: 10.1038/sj.bmt.1703820.
本文引用的文献
1
Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.尼洛替尼预防对晚期慢性髓性白血病或费城染色体阳性急性淋巴细胞白血病患者异基因干细胞移植后的免疫效应。
Oncotarget. 2017 Jan 3;8(1):418-429. doi: 10.18632/oncotarget.13439.
2
transcripts (MR) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.移植后3个月的转录本（MR）作为慢性髓性白血病长期预后的早期预测指标。
Korean J Intern Med. 2017 Jan;32(1):125-136. doi: 10.3904/kjim.2015.187. Epub 2016 Jun 22.
3
Moving treatment-free remission into mainstream clinical practice in CML.推动无治疗缓解进入 CML 的主流临床实践。
Blood. 2016 Jul 7;128(1):17-23. doi: 10.1182/blood-2016-01-694265. Epub 2016 Mar 24.
4
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
5
Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.异基因造血干细胞移植治疗慢性髓性白血病后第100天BCR-ABL定量对复发的预测
Leukemia. 2006 May;20(5):793-9. doi: 10.1038/sj.leu.2404170.
6
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.监测接受酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者：关于统一当前检测BCR-ABL转录本和激酶结构域突变方法以及结果表达的综述与建议。
Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7.
7
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.慢性髓性白血病异基因造血干细胞移植后外周血中BCR-ABL转录本的系列检测：确定可能无需进一步治疗患者的尝试。
Blood. 2006 May 15;107(10):4171-6. doi: 10.1182/blood-2005-08-3320. Epub 2006 Jan 31.
8
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.通过定量逆转录聚合酶链反应早期检测BCR-ABL转录本可预测慢性髓性白血病异基因干细胞移植后的结局。
Blood. 2001 Mar 15;97(6):1560-5. doi: 10.1182/blood.v97.6.1560.
Zotero 插件